ICAGEN/PFIZER INITIATE STUDY FOR PAIN/RELATED DISORDERS.
P. Kay Wagoner, CEO of Icagen, stated, "We are very pleased to report positive progress in our sodium channel pain collaboration with Pfizer in which compounds are now being advanced into first-in-man studies. As we have reported previously, the scientific partnership between Icagen and Pfizer has been successful in identifying novel, potent and selective blockers of the sodium channel Nav1.7, also referred to as SCN9A. Loss of function mutations of this channel have been genetically linked to the congenital inability to experience pain, and conversely gain of function mutations are implicated in the pain underlying primary erythromelalgia and paroxysmal extreme pain disorder. Based upon these genetic linkages, Nav1.7 is believed to be among the most promising targets for new pain therapeutics."
Gillian Burgess, Chief Scientific Officer of Pfizer's Pain Research Unit, stated, "We are pleased with the work we have done with Icagen on sodium channels for pain. We believe that the joint identification of these proprietary molecules targeting sodium channels in our collaboration is an exciting advance in this field."
Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The company is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. The company has a clinical stage program in epilepsy and pain.
For more information, visit http://www.icagen.com or call 919/941-5206.
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 28, 2010|
|Previous Article:||CHELSEA THERAPEUTICS INITIATES 306 PHASE III NOH TRIAL.|
|Next Article:||OXYGEN BIOTHERAPEUTICS DEBUTS OXYGEN-RICH SERUM.|